Arrowhead Pharmaceuticals Announces $700M Combined Equity and Convertible Note Offering

summarizeSummary

Arrowhead Pharmaceuticals is undertaking a significant capital raise of $700 million through a concurrent common stock offering and convertible senior notes to fund operations, R&D, and commercialization efforts into fiscal year 2029.

check_boxKey Events

• Common Stock Offering

  The company is offering $200 million of its common stock. The last reported sale price on January 5, 2026, was $63.88 per share, compared to today's price of $65.70.

• Concurrent Convertible Note Offering

  Concurrently, Arrowhead is offering $500 million in convertible senior notes due 2032, with an option for underwriters to purchase an additional $75 million. This adds to the total capital raised and introduces potential future dilution upon conversion.

• Extended Financial Runway

  The combined net proceeds from both offerings are projected to fund the company's operations, including R&D and commercialization, into fiscal year 2029, significantly extending its financial runway.

• Use of Proceeds

  Proceeds will be used for general corporate purposes, including working capital, capital expenditures, research and development, clinical trials, and commercialization activities, with a portion potentially used to prepay loans under the Credit Facility.

auto_awesomeAnalysis

This substantial capital raise, combining a $200 million common stock offering and a $500 million convertible senior note offering, is a critical financing event for Arrowhead Pharmaceuticals. While the equity component will result in dilution for existing shareholders, the combined proceeds are expected to fund the company's operations, including research and development, clinical trials, and commercialization activities for its recently approved product REDEMPLO and late-stage pipeline, into fiscal year 2029. For a life sciences company, securing such a long financial runway is a significant positive, reducing near-term funding risks and supporting continued growth and product development. Investors should monitor the final pricing of the offerings and the impact of the convertible notes on future share count.